# EDGAR Filing Document

**Accession Number:** 0001706431
**File Stem:** 0001193125-23-039075
**Filing Date:** 2023-2
**Character Count:** 16129
**Document Hash:** 2c621d20fcce65cde65fb5b74a367b78
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-23-039075.hdr.sgml**: 20230214

**ACCESSION NUMBER**: 0001193125-23-039075

**CONFORMED SUBMISSION TYPE**: SC 13G/A

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20230214

**DATE AS OF CHANGE**: 20230214

**GROUP MEMBERS**: SB INVESTMENT ADVISERS (UK) LTD

**GROUP MEMBERS**: SVF ENDURANCE (CAYMAN) LTD

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Vir Biotechnology, Inc.
- **CENTRAL INDEX KEY:** 0001706431
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **IRS NUMBER:** 812730369
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC 13G/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-91177
- **FILM NUMBER:** 23629079

**BUSINESS ADDRESS:**
- **STREET 1:** 499 ILLINOIS STREET
- **STREET 2:** SUITE 500
- **CITY:** SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94158
- **BUSINESS PHONE:** 415-906-4324

**MAIL ADDRESS:**
- **STREET 1:** 499 ILLINOIS STREET
- **STREET 2:** SUITE 500
- **CITY:** SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94158
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** SOFTBANK VISION FUND (AIV M1) L.P.
- **CENTRAL INDEX KEY:** 0001755143
- **IRS NUMBER:** 821553321
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC 13G/A

**BUSINESS ADDRESS:**
- **STREET 1:** 251 LITTLE FALLS DRIVE
- **CITY:** WILMINGTON
- **STATE:** DE
- **ZIP:** 19808
- **BUSINESS PHONE:** 650-562-8211

**MAIL ADDRESS:**
- **STREET 1:** 251 LITTLE FALLS DRIVE
- **CITY:** WILMINGTON
- **STATE:** DE
- **ZIP:** 19808

------

------

**Securities and Exchange Commission** 

**Washington, D.C. 20549** 

------

**Schedule 13G** 

**(Rule 13d-102)** 

**Information to be Included in Statements Filed Pursuant** 

**to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed** 

**Pursuant to § 240.13d-2** 

**UNDER THE SECURITIES EXCHANGE ACT OF 1934** 

**(Amendment No. 1)\*** 

------

## Vir Biotechnology, Inc.
**(Name of Issuer)** 

**Common Stock** 

**(Title of Class of Securities)** 

**92764N102** 

**(CUSIP Number)** 

**December 31, 2022** 

**(Date of Event Which Requires Filing of this Statement)** 

------

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☐ Rule 13d-1(c)

☒ Rule 13d-1(d)

\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

------

CUSIP No. 92764N102 Schedule 13G Page 1 of 8

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp; 1 | &nbsp;&nbsp;&nbsp;&nbsp;Names of Reporting Persons<br>&nbsp;&nbsp;&nbsp;&nbsp;**SVF Endurance (Cayman) Limited** |
| &nbsp;&nbsp;&nbsp; 2 | &nbsp;&nbsp;&nbsp;&nbsp;Check the Appropriate Box if a Member of a Group<br> &nbsp;&nbsp;&nbsp;&nbsp;(a) ☐ (b) ☐ |
| &nbsp;&nbsp;&nbsp; 3 | &nbsp;&nbsp;&nbsp;&nbsp;SEC Use Only |
| &nbsp;&nbsp;&nbsp; 4 | &nbsp;&nbsp;&nbsp;&nbsp;Citizenship or Place of Organization<br>&nbsp;&nbsp;&nbsp;&nbsp;**Cayman Islands** |

---

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;&nbsp; Number of<br> Shares<br> Beneficially <br> Owned by<br> Each<br> Reporting<br> Person<br> With | 5 | &nbsp;&nbsp;&nbsp;&nbsp;Sole Voting Power<br>&nbsp;&nbsp;&nbsp;&nbsp;**0** |
| &nbsp;&nbsp;&nbsp; Number of<br> Shares<br> Beneficially <br> Owned by<br> Each<br> Reporting<br> Person<br> With | 6 | &nbsp;&nbsp;&nbsp;&nbsp;Shared Voting Power<br>&nbsp;&nbsp;&nbsp;&nbsp;**20,259,535** |
| &nbsp;&nbsp;&nbsp; Number of<br> Shares<br> Beneficially <br> Owned by<br> Each<br> Reporting<br> Person<br> With | 7 | &nbsp;&nbsp;&nbsp;&nbsp;Sole Dispositive Power<br>&nbsp;&nbsp;&nbsp;&nbsp;**0** |
| &nbsp;&nbsp;&nbsp; Number of<br> Shares<br> Beneficially <br> Owned by<br> Each<br> Reporting<br> Person<br> With | 8 | &nbsp;&nbsp;&nbsp;&nbsp;Shared Dispositive Power<br>&nbsp;&nbsp;&nbsp;&nbsp;**20,259,535** |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp; 9 | &nbsp;&nbsp;&nbsp;&nbsp;Aggregate Amount Beneficially Owned by Each Reporting Person<br>&nbsp;&nbsp;&nbsp;&nbsp;**20,259,535** |
| &nbsp;&nbsp;&nbsp;10 | &nbsp;&nbsp;&nbsp;&nbsp;Check if the Aggregate Amount in Row (9) Excludes Certain Shares<br>&nbsp;&nbsp;&nbsp;&nbsp;**Not Applicable** |
| &nbsp;&nbsp;&nbsp;11 | &nbsp;&nbsp;&nbsp;&nbsp;Percent of Class Represented by Amount in Row 9<br>&nbsp;&nbsp;&nbsp;&nbsp;**15.2%** |
| &nbsp;&nbsp;&nbsp;12 | &nbsp;&nbsp;&nbsp;&nbsp;Type of Reporting Person<br>&nbsp;&nbsp;&nbsp;&nbsp;**CO** |

---

------

CUSIP No. 92764N102 Schedule 13G Page 2 of 8

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp; 1 | &nbsp;&nbsp;&nbsp;&nbsp;Names of Reporting Persons<br>&nbsp;&nbsp;&nbsp;&nbsp;**SoftBank Vision Fund (AIV M1) L.P.** |
| &nbsp;&nbsp;&nbsp; 2 | &nbsp;&nbsp;&nbsp;&nbsp;Check the Appropriate Box if a Member of a Group<br> &nbsp;&nbsp;&nbsp;&nbsp;(a) ☐ (b) ☐ |
| &nbsp;&nbsp;&nbsp; 3 | &nbsp;&nbsp;&nbsp;&nbsp;SEC Use Only |
| &nbsp;&nbsp;&nbsp; 4 | &nbsp;&nbsp;&nbsp;&nbsp;Citizenship or Place of Organization<br>&nbsp;&nbsp;&nbsp;&nbsp;**Delaware** |

---

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;&nbsp; Number of<br> Shares<br> Beneficially <br> Owned by<br> Each<br> Reporting<br> Person<br> With | 5 | &nbsp;&nbsp;&nbsp;&nbsp;Sole Voting Power<br>&nbsp;&nbsp;&nbsp;&nbsp;**0** |
| &nbsp;&nbsp;&nbsp; Number of<br> Shares<br> Beneficially <br> Owned by<br> Each<br> Reporting<br> Person<br> With | 6 | &nbsp;&nbsp;&nbsp;&nbsp;Shared Voting Power<br>&nbsp;&nbsp;&nbsp;&nbsp;**20,259,535** |
| &nbsp;&nbsp;&nbsp; Number of<br> Shares<br> Beneficially <br> Owned by<br> Each<br> Reporting<br> Person<br> With | 7 | &nbsp;&nbsp;&nbsp;&nbsp;Sole Dispositive Power<br>&nbsp;&nbsp;&nbsp;&nbsp;**0** |
| &nbsp;&nbsp;&nbsp; Number of<br> Shares<br> Beneficially <br> Owned by<br> Each<br> Reporting<br> Person<br> With | 8 | &nbsp;&nbsp;&nbsp;&nbsp;Shared Dispositive Power<br>&nbsp;&nbsp;&nbsp;&nbsp;**20,259,535** |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp; 9 | &nbsp;&nbsp;&nbsp;&nbsp;Aggregate Amount Beneficially Owned by Each Reporting Person<br>&nbsp;&nbsp;&nbsp;&nbsp;**20,259,535** |
| &nbsp;&nbsp;&nbsp;10 | &nbsp;&nbsp;&nbsp;&nbsp;Check if the Aggregate Amount in Row (9) Excludes Certain Shares<br>&nbsp;&nbsp;&nbsp;&nbsp;**Not Applicable** |
| &nbsp;&nbsp;&nbsp;11 | &nbsp;&nbsp;&nbsp;&nbsp;Percent of Class Represented by Amount in Row 9<br>&nbsp;&nbsp;&nbsp;&nbsp;**15.2%** |
| &nbsp;&nbsp;&nbsp;12 | &nbsp;&nbsp;&nbsp;&nbsp;Type of Reporting Person<br>&nbsp;&nbsp;&nbsp;&nbsp;**PN** |

---

------

CUSIP No. 92764N102 Schedule 13G Page 3 of 8

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp; 1 | &nbsp;&nbsp;&nbsp;&nbsp;Names of Reporting Persons<br>&nbsp;&nbsp;&nbsp;&nbsp;**SB Investment Advisers (UK) Limited** |
| &nbsp;&nbsp;&nbsp; 2 | &nbsp;&nbsp;&nbsp;&nbsp;Check the Appropriate Box if a Member of a Group<br> &nbsp;&nbsp;&nbsp;&nbsp;(a) ☐ (b) ☐ |
| &nbsp;&nbsp;&nbsp; 3 | &nbsp;&nbsp;&nbsp;&nbsp;SEC Use Only |
| &nbsp;&nbsp;&nbsp; 4 | &nbsp;&nbsp;&nbsp;&nbsp;Citizenship or Place of Organization<br>&nbsp;&nbsp;&nbsp;&nbsp;**England and Wales** |

---

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;&nbsp; Number of<br> Shares<br> Beneficially <br> Owned by<br> Each<br> Reporting<br> Person<br> With | 5 | &nbsp;&nbsp;&nbsp;&nbsp;Sole Voting Power<br>&nbsp;&nbsp;&nbsp;&nbsp;**0** |
| &nbsp;&nbsp;&nbsp; Number of<br> Shares<br> Beneficially <br> Owned by<br> Each<br> Reporting<br> Person<br> With | 6 | &nbsp;&nbsp;&nbsp;&nbsp;Shared Voting Power<br>&nbsp;&nbsp;&nbsp;&nbsp;**20,259,535** |
| &nbsp;&nbsp;&nbsp; Number of<br> Shares<br> Beneficially <br> Owned by<br> Each<br> Reporting<br> Person<br> With | 7 | &nbsp;&nbsp;&nbsp;&nbsp;Sole Dispositive Power<br>&nbsp;&nbsp;&nbsp;&nbsp;**0** |
| &nbsp;&nbsp;&nbsp; Number of<br> Shares<br> Beneficially <br> Owned by<br> Each<br> Reporting<br> Person<br> With | 8 | &nbsp;&nbsp;&nbsp;&nbsp;Shared Dispositive Power<br>&nbsp;&nbsp;&nbsp;&nbsp;**20,259,535** |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp; 9 | &nbsp;&nbsp;&nbsp;&nbsp;Aggregate Amount Beneficially Owned by Each Reporting Person<br>&nbsp;&nbsp;&nbsp;&nbsp;**20,259,535** |
| &nbsp;&nbsp;&nbsp;10 | &nbsp;&nbsp;&nbsp;&nbsp;Check if the Aggregate Amount in Row (9) Excludes Certain Shares<br>&nbsp;&nbsp;&nbsp;&nbsp;**Not Applicable** |
| &nbsp;&nbsp;&nbsp;11 | &nbsp;&nbsp;&nbsp;&nbsp;Percent of Class Represented by Amount in Row 9<br>&nbsp;&nbsp;&nbsp;&nbsp;**15.2%** |
| &nbsp;&nbsp;&nbsp;12 | &nbsp;&nbsp;&nbsp;&nbsp;Type of Reporting Person<br>&nbsp;&nbsp;&nbsp;&nbsp;**CO** |

---

------

CUSIP No. 92764N102 Schedule 13G Page 4 of 8

---

| | |
|:---|:---|
| **ITEM 1.** | **(a) Name of Issuer:**  |

---

Vir Biotechnology, Inc. (the "Issuer").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(b)** **Address of Issuer's Principal Executive Offices:** 

499 Illinois Street, Suite 500, San Francisco, CA 94158

---

| | |
|:---|:---|
| **ITEM 2.** | **(a) Name of Person Filing:**  |

---

Each of the following is hereinafter individually referred to as a "Reporting Person" and collectively as the "Reporting Persons." This statement is filed on behalf of:

SVF Endurance (Cayman) Limited

SoftBank Vision Fund (AIV M1) L.P. ("SVF")

SB Investment Advisers (UK) Limited ("SBIA UK")

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(b)** **Address or Principal Business Office:** 

The principal business address of SVF Endurance (Cayman) Limited is c/o Walkers Corporate Ltd., 190 Elgin Avenue, George Town, Grand Cayman KY1-9008. The principal business address of SVF is 251 Little Falls Drive Wilmington, DE 19808. The principal business address of SBIA UK is 69 Grosvenor Street, London, United Kingdom, W1K 3JP.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(c)** **Citizenship of each Reporting Person is:** 

SVF Endurance (Cayman) Limited is organized under the laws of the Cayman Islands. SVF is organized under the laws of the State of Delaware. SBIA UK is organized under the laws of England and Wales.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(d)** **Title of Class of Securities:** 

Common stock, par value $0.0001 per share ("Common Stock").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(e)** **CUSIP Number:** 

92764N102

**ITEM 3.**

Not applicable.

------

CUSIP No. 92764N102 Schedule 13G Page 5 of 8

---

| | |
|:---|:---|
| **ITEM 4.** | **Ownership.**  |

---

**(a-c)** 

The ownership information presented below represents beneficial ownership of Common Stock of the Issuer as of December 31, 2022, based upon 133,115,621 shares of Common Stock outstanding as of October 31, 2022, as disclosed in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 3, 2022.

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Reporting Person** | **Amount**<br> **beneficially**<br> **owned** | **Percent**<br> **of class:** | **Sole power<br>to vote or to<br>direct the<br>vote:** | **Shared power<br>to vote or to<br>direct the vote:** | **Sole<br>power to<br>dispose or<br>to direct<br>the<br>disposition**<br> **of:** | **Shared**<br> **power to**<br> **dispose or**<br> **to direct**<br> **the**<br> **disposition**<br> **of:** |
|  SVF Endurance (Cayman) Limited | 20259535 | 15.2% | 0 | 20259535 | 0 | 20259535 |
|  SoftBank Vision Fund (AIV M1) L.P. | 20259535 | 15.2% | 0 | 20259535 | 0 | 20259535 |
|  SB Investment Advisers (UK) Limited | 20259535 | 15.2% | 0 | 20259535 | 0 | 20259535 |

---

SVF Endurance (Cayman) Limited is the record holder of the shares of Common Stock reported herein. SVF is the sole owner of SVF Endurance (Cayman) Limited.

SBIA UK has been appointed as alternative investment fund manager ("AIFM") of SVF. SBIA UK is authorized and regulated by the UK Financial Conduct Authority and is exclusively responsible for making all decisions related to the acquisition, structuring, financing and disposal of SVF's investments. As a result of these relationships, each of the Reporting Persons may be deemed to share beneficial ownership of the securities reported herein.

---

| | |
|:---|:---|
| **ITEM 5.** | **Ownership of Five Percent or Less of a Class.**  |

---

Not applicable.

---

| | |
|:---|:---|
| **ITEM 6.** | **Ownership of More than Five Percent on Behalf of Another Person.**  |

---

Not applicable.

---

| | |
|:---|:---|
| **ITEM 7.** | **Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.**  |

---

Not applicable.

---

| | |
|:---|:---|
| **ITEM 8.** | **Identification and Classification of Members of the Group.**  |

---

Not applicable.

------

CUSIP No. 92764N102 Schedule 13G Page 6 of 8

---

| | |
|:---|:---|
| **ITEM 9.** | **Notice of Dissolution of Group.**  |

---

Not applicable.

---

| | |
|:---|:---|
| **ITEM 10.** | **Certification.**  |

---

Not applicable.

------

CUSIP No. 92764N102 Schedule 13G Page 7 of 8

**SIGNATURE** 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Date**: February 13, 2023

---

| | |
|:---|:---|
| **SVF Endurance (Cayman) Limited** | **SVF Endurance (Cayman) Limited** |
| By: | /s/ Karen Ellerbe |
| Name: | Karen Ellerbe |
| Title: | Director |
| **SoftBank Vision Fund (AIV M1) L.P.** | **SoftBank Vision Fund (AIV M1) L.P.** |
| By: SB Investment Advisers (UK) Limited, its manager | By: SB Investment Advisers (UK) Limited, its manager |
| By: | /s/ Amanda Sanchez-Barry |
| Name: | Amanda Sanchez-Barry |
| Title: | General Counsel |
| **SB Investment Advisers (UK) Limited** | **SB Investment Advisers (UK) Limited** |
| By: | /s/ Amanda Sanchez-Barry |
| Name: | Amanda Sanchez-Barry |
| Title: | General Counsel |

---

------

CUSIP No. 92764N102 Schedule 13G Page 8 of 8

**LIST OF EXHIBITS** 

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 99 | Joint Filing Agreement. |

---

## Ex-99

**Exhibit 99** 

**JOINT FILING AGREEMENT** 

In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that they are jointly filing this statement on Schedule 13G. Each of them is responsible for the timely filing of such statement and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the completeness or accuracy of the information concerning the other persons making the filing, unless such person knows or has reason to believe that such information is inaccurate.

IN WITNESS WHEREOF, the undersigned hereby execute this Joint Filing Agreement as of February 13, 2023.

---

| | |
|:---|:---|
| **SVF Endurance (Cayman) Limited** | **SVF Endurance (Cayman) Limited** |
| By: | /s/ Karen Ellerbe |
| Name: | Karen Ellerbe |
| Title: | Director |
| **SoftBank Vision Fund (AIV M1) L.P.** | **SoftBank Vision Fund (AIV M1) L.P.** |
| By: SB Investment Advisers (UK) Limited, its manager | By: SB Investment Advisers (UK) Limited, its manager |
| By: | /s/ Amanda Sanchez-Barry |
| Name: | Amanda Sanchez-Barry |
| Title: | General Counsel |
| **SB Investment Advisers (UK) Limited** | **SB Investment Advisers (UK) Limited** |
| By: | /s/ Amanda Sanchez-Barry |
| Name: | Amanda Sanchez-Barry |
| Title: | General Counsel |

---